Dopamine agonist and antagonist activities of piribedil (ET495)and its metabolites.
D000547:Amantadine / Q000494:pharmacology; D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001285:Atropine / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D002421:Caudate Nucleus; D003913:Dextroamphetamine / Q000494:pharmacology; D004149:Dioxoles / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology; D004298:Dopamine / Q000494:pharmacology*; D018492:Dopamine Antagonists; D004357:Drug Synergism; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D007267:Injections; D008297:Male; D008774:Methylphenidate / Q000494:pharmacology; D009043:Motor Activity / Q000187:drug effects; D009526:Nialamide / Q000494:pharmacology; D010879:Piperazines / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D011743:Pyrimidines / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology; D051381:Rats; D013239:Stereotyped Behavior / Q000187:drug effects; D013447:Sulfites / Q000494:pharmacology
D004149:Dioxoles; D018492:Dopamine Antagonists; D010879:Piperazines; D011743:Pyrimidines; D013447:Sulfites; D008774:Methylphenidate; D001285:Atropine; D000547:Amantadine; D000661:Amphetamine; D006220:Haloperidol; D001058:Apomorphine; D009526:Nialamide; D003913:Dextroamphetamine; D004298:Dopamine